Pharmacokinetic/pharmacodynamic-guided gentamicin dosing in critically ill patients: a revisit of the Hartford nomogram.

Int J Antimicrob Agents

Division of Biopharmaceutics and Pharmacokinetics, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410013, China. Electronic address:

Published: June 2022

The appropriateness of the Hartford nomogram based on 7 mg/kg gentamicin with administration interval adjustment is questioned in critically ill patients. This study aimed to perform a pharmacokinetic/pharmacodynamic (PK/PD) evaluation of the Hartford nomogram and to assess the influence of PK/PD indices on gentamicin dosing. Gentamicin data were extracted from a critical care database to construct the population PK model. Simulations were performed to evaluate the probability of target attainment (PTA) and risk of toxicity for the gentamicin Hartford nomogram. C/MIC ≥ 10 and AUC/MIC ≥ 100 were the PK/PD targets considered, and the non-toxicity targets included concentration < 0.5 mg/L for at least 4 h within a dosing interval and trough concentration < 1 mg/L. A one-compartment model was optimal to describe gentamicin PKs, and creatinine clearance (CL) was included as a time-varying covariate on gentamicin clearance. The PTA of C/MIC ≥ 10 (MIC = 1 mg/L) for the Hartford nomogram was suboptimal after the first dose but was desirable (near or greater than 90%) at steady-state, and > 90% PTA based on AUC/MIC ≥ 100 was readily achieved after the first dose in patients with CL < 60 mL/min. Significant PTA differences between the PK/PD targets were observed at an MIC of 2 mg/L, but the PTAs were all low. The predicted risk of toxicity was high regardless of the applied toxicity targets. The Hartford nomogram provided adequate gentamicin exposure in critically ill patients with an MIC ≤ 1 mg/L by considering the combined PK/PD indices.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijantimicag.2022.106600DOI Listing

Publication Analysis

Top Keywords

hartford nomogram
24
critically ill
12
ill patients
12
gentamicin dosing
8
pk/pd indices
8
risk toxicity
8
c/mic ≥
8
auc/mic ≥
8
≥ 100
8
pk/pd targets
8

Similar Publications

Malignancy after heart transplantation is associated with poor outcomes. At present, no prediction model exists for any malignancy within the first year after transplant. We studied adults who underwent heart transplantation included in the multicenter, national Scientific Registry of Transplant Recipients from January 2000 through April 2021.

View Article and Find Full Text PDF

Pharmacokinetic/pharmacodynamic-guided gentamicin dosing in critically ill patients: a revisit of the Hartford nomogram.

Int J Antimicrob Agents

June 2022

Division of Biopharmaceutics and Pharmacokinetics, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410013, China. Electronic address:

The appropriateness of the Hartford nomogram based on 7 mg/kg gentamicin with administration interval adjustment is questioned in critically ill patients. This study aimed to perform a pharmacokinetic/pharmacodynamic (PK/PD) evaluation of the Hartford nomogram and to assess the influence of PK/PD indices on gentamicin dosing. Gentamicin data were extracted from a critical care database to construct the population PK model.

View Article and Find Full Text PDF

Objectives: Extended-interval dosing of tobramycin is widely applied in patients with the Hartford nomogram as a representative, while this dosing approach has not been extensively evaluated in critically ill patients. The goal of this study was to characterize the pharmacokinetics of tobramycin and to evaluate the appropriateness of the Hartford nomogram in critically ill patients.

Methods: A retrospective analysis was performed based on a medical critical care database.

View Article and Find Full Text PDF

Purpose Of Review: Antimicrobial resistance among Gram-negative organisms is a rapidly escalating global challenge. Pharmacologic dose optimization based on pharmacokinetic/pharmacodynamic principles is essential for managing Gram-negative infections. High-risk patient populations may receive nonoptimized antimicrobial dosing because pf physiologic changes in acute illness and/or medical interventions.

View Article and Find Full Text PDF

Plazomicin is a new FDA-approved aminoglycoside antibiotic for complicated urinary tract infections (cUTI). In the product labeling, trough-based therapeutic drug management (TDM) is recommended for cUTI patients with renal impairment to prevent elevated trough concentrations associated with serum creatinine increases of ≥0.5 mg/dl above baseline.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!